Company intelligence / Profile preview
Atopia Therapeutics
Geneva, Geneva Canton, Switzerlandatopiatx.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Preclinical studies of ATP-R13 have shown promising results in murine models of allergic asthma, demonstrating improved airway responsiveness, reduced airway remodeling, and decreased inflammation. The therapy induces immune tolerance by promoting regulatory T cell development and aims to address the root cause of allergic diseases rather than just symptoms. Clinical development preparations are ongoing.[3][7]
- Therapeutic areas
- PulmonologyDermatologyImmunology
- Modalities
- Oral immunotherapyrecombinant protein (bacterial protein-derived)immunomodulatory biologic[1][5][9]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
None publicly disclosed as of May 2024.
Beyond the preview
Go deeper on Atopia Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Atopia Therapeutics.